Skip to main content

Epistem Aims to Raise £2.8M

NEW YORK (GenomeWeb News) – Epistem Holdings said that it plans to raise £2.8 million ($4.4 million) through the placement of 793,398 new ordinary shares at 350 pence each.

The offering price is a slight discount to the trading price of around 362.5 pence before the placement was announced Friday. The Manchester, UK-based firm said that it has conditionally placed the shares with unnamed existing and new institutional investors.

Epistem plans to use the proceeds from the placement to accelerate development of its Genedrive point-of-care device for molecular diagnostics, pharmacogenomics, biodefense, and forensic applications. The firm said the system, which it is developing for bacterial, viral, fungal, and gene mutations, is in clinical trials across a number of diagnostic areas.

Epistem also has biomarker deals with several pharmaceutical firms including Sanofi-Aventis, Novartis, AstraZeneca, and Johnson & Johnson.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.